Illumina Inc

Find Ratings Reports
ILMN : NASDAQ : Health Care
$182.99 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 973200.0
06/22/17 - 4:00 PM ET

Financial Analysis


ILLUMINA INC's gross profit margin for the first quarter of its fiscal year 2017 has decreased when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not. ILLUMINA INC is extremely liquid. Currently, the Quick Ratio is 2.98 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has greatly increased by 28.11% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q1 FY17 Q1 FY16
Net Sales ($mil)598.0571.76
EBITDA ($mil)120.4157.75
EBIT ($mil)82.4124.53
Net Income ($mil)367.089.59


Balance Sheet Q1 FY17 Q1 FY16
Cash & Equiv. ($mil)1778.01343.09
Total Assets ($mil)4598.03793.71
Total Debt ($mil)1056.01022.65
Equity ($mil)2551.01991.11


Profitability Q1 FY17 Q1 FY16
Gross Profit Margin70.975.25
EBITDA Margin20.1327.58
Operating Margin13.7821.78
Sales Turnover0.530.59
Return on Assets16.0910.92
Return on Equity29.0120.81
Debt Q1 FY17 Q1 FY16
Current Ratio3.494.31
Debt/Capital0.290.34
Interest Expense8.08.53
Interest Coverage10.314.61


Share Data Q1 FY17 Q1 FY16
Shares outstanding (mil)146.0147.2
Div / share0.00.0
EPS2.480.6
Book value / share17.4713.53
Institutional Own % n/a n/a
Avg Daily Volume989445.01099270.0

Valuation


BUY. This stock's P/E ratio indicates a significant discount compared to an average of 50.44 for the Life Sciences Tools & Services industry and a premium compared to the S&P 500 average of 25.73. For additional comparison, its price-to-book ratio of 9.85 indicates a significant premium versus the S&P 500 average of 3.08 and a significant premium versus the industry average of 6.60. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. The valuation analysis reveals that, ILLUMINA INC seems to be trading at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ILMN 34.34 Peers 50.44   ILMN 30.82 Peers 30.10

Discount. A lower P/E ratio than its peers can signify a less expensive stock or lower growth expectations.

ILMN is trading at a significant discount to its peers.

 

Average. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ILMN is trading at a valuation on par to its peers.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
ILMN 39.50 Peers 28.59   ILMN 1.82 Peers 0.96

Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.

ILMN is trading at a significant premium to its peers.

 

Premium. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

ILMN trades at a significant premium to its peers.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ILMN 9.85 Peers 6.60   ILMN 80.21 Peers 15.03

Premium. A higher price-to-book ratio makes a stock less attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ILMN is trading at a significant premium to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

ILMN is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ILMN 10.36 Peers 19.27   ILMN 7.61 Peers 10.10

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ILMN is trading at a significant discount to its industry on this measurement.

 

Lower. A sales growth rate that trails the industry implies that a company is losing market share.

ILMN trails its peers on the basis of sales growth

 

 

Latest Stock Upgrades/Downgrades